An assay for anti-factor Xa activity of low molecular weight heparins by high performance liquid size exclusion chromatography

被引:7
|
作者
Zhang Qianqian [1 ]
Kang Jingwu [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Organ Chem, Shanghai 200032, Peoples R China
关键词
size exclusion chromatography (SEC); anti-factor Xa activity; low molecular weight heparins;
D O I
10.3724/SP.J.1123.2013.04029
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The "gold standard" assay for monitoring low molecular weight heparins (LMWHs) activity is the chromogenic-based anti-factor Xa assay. The methodology of an anti-factor Xa assay is that LMWH is added to a known amount of excess factor Xa and excess antithrombin. It will bind to antithrombin and form a triplet complex with factor Xa, inhibiting the activity of factor Xa. However, the residual factor Xa can still hydrolyze chromogenic peptide substrate, releasing the chromophore for photometric detection. The absorbance is inversely proportional to the amount of heparin/LMWH. The results are given in anticoagulant concentration in units/ mL of anti-factor Xa, such that high values indicate high levels of anticoagulation and low values indicate low levels of anticoagulation. Herein, a novel assay method for anti-FXa activity of LMWHs using high performance liquid size exclusion chromatography (SEC) is reported, in which antithrombin III (AT III) was diluted by the buffer solution contained LMWHs. Subsequently, exogenous FXa and p-nitroaniline coupled peptide substrate were added and incubated for a period, separately. The resulting mixture was separated based on size by SEC, and the free chromophore p-nitroaniline can be detected at an absorption maximum of 385 nm without interference from the absorbance of p-nitroanilide substrates. Moreover, the measurements are not influenced by sample opacity or turbidity, so it is possible to test various complex samples, such as plasma. The assay is robust, sensitive, and cost effective.
引用
收藏
页码:684 / 690
页数:7
相关论文
共 17 条
  • [1] The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin
    Anand, S
    Ginsberg, JS
    Kearon, C
    Gent, M
    Hirsh, J
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (15) : 1677 - 1681
  • [2] Guidelines on the use and monitoring of heparin
    Baglin, T
    Barrowcliffe, TW
    Cohen, A
    Greaves, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 (01) : 19 - 34
  • [3] Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs
    Castro-Lopez, Vanessa
    Harris, Leanne F.
    O'Donnell, James S.
    Killard, Anthony J.
    [J]. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2011, 399 (02) : 691 - 700
  • [4] Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency
    Clark, N. P.
    [J]. THROMBOSIS RESEARCH, 2008, 123 : S58 - S61
  • [5] Greaves M, 2002, THROMB HAEMOSTASIS, V87, P163
  • [6] Hammerstingl C., 2008, Cardiovascular & Hematological Agents in Medicinal Chemistry, V6, P282, DOI 10.2174/187152508785909492
  • [7] Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays
    Harris, Leanne F.
    O'Brien, Aoife
    Castro-Lopez, Vanessa
    O'Donnell, James S.
    Killard, Anthony J.
    [J]. THROMBOSIS RESEARCH, 2011, 128 (06) : E166 - E170
  • [8] Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas
    Harris, Leanne F.
    Castro-Lopez, Vanessa
    Jenkins, P. Vince
    O'Donnell, James S.
    Killard, Anthony J.
    [J]. THROMBOSIS RESEARCH, 2011, 128 (06) : E125 - E129
  • [9] Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins
    Harris, Leanne F.
    Castro-Lopez, Vanessa
    Hammadi, Nissrin
    O'Donnell, James S.
    Killard, Anthony J.
    [J]. TALANTA, 2010, 81 (4-5) : 1725 - 1730
  • [10] Heparin and low-molecular-weight heparin - The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Hirsh, J
    Raschke, R
    [J]. CHEST, 2004, 126 (03) : 188S - 203S